Medical/Pharmaceuticals
A large international study of migraine reveals new biological pathways for treatment
REYKJAVIK, Iceland, Oct. 26, 2023 /PRNewswire/ -- A large international study led by deCODE Genetics on the genetics of migraine provides novel insights into the biology of migraine enabling detection of rare variants protecting against migraine, opening an avenue for potential development of nov...
2023-10-26 23:00
2171
Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
* Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services forHope Medicine's first-in-class monoclonal antibody drug, HMI-115. * The first-in-class mAb will benefit endometriosis and androgenetic alopecia patients. SHANGHAI, Oct. 26, 20...
2023-10-26 22:49
1582
Clarity and PSI kick off SAR-bisPSMA Phase III
SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG ("PSI"), a global contract rese...
2023-10-26 21:00
1513
ZEISS continues to expand its clinical workflows and digital portfolio, presenting new tools and solutions at AAO 2023
* ZEISS CT LUCIA 621P is now available for calculation on the ZEISS AI IOL Calculator. * New ZEISS PROSPARA digital marketing software within the ZEISS Corneal Refractive Workflow helps enhance online visibility for refractive practices. * ZEISS VISULAS yag therapeutic laser receives 510k cl...
2023-10-26 21:00
1653
YS Biopharma Announces Receipt of Nasdaq Notice
GAITHERSBURG, Md., Oct. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-10-26 20:30
3496
HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
* Sales recorded KRW 33 billion in Q3 2023, an 11 percent increase from the same period in 2022, due to the sustained growth of major products. * 'HL161ANS', HanAll's second anti-FcRn antibody, demonstrated best-in-class potential through the initial outcome of Phase 1 study. * 'HL192', a Nu...
2023-10-26 19:00
1747
Fapon, LASCCO, Abionic Formed Strategic Collaboration for PSP Sepsis Diagnosis in China
LAUSANNE, Switzerland, Oct. 26, 2023 /PRNewswire/ -- Fapon, a leading life sciences company, entered into a strategic cooperation agreement with two Swiss biotech companies LASCCO SA and Abionic SA, that granted Fapon an exclusive license to utilize the pancreatic stone protein (PSP) biomarker fo...
2023-10-26 18:33
2428
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA
SINGAPORE, Oct. 26, 2023 /PRNewswire/ -- On October 26, 2023, Biosyngen's TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in the field of cell and gene therapy, represents the world's first TIL therapy designed for the tre...
2023-10-26 18:18
2665
JINGHAO MEDICAL's self-fitting OTC hearing aids received FDA 510(k) approval
HONGKONG, SHANGHAI, and BEIJING, Oct. 26, 2023 /PRNewswire/ -- As the first hearing aid manufacturer to be listed in China, JINGHAO MEDICAL has once again taken a historic step. OnSeptember 26, 2023, the self-fitting OTC hearing aid developed and manufactured by JINGHAO MEDICAL officially receive...
2023-10-26 17:38
1599
World Psoriasis Day 2023: Access for All
STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- Every year on World Psoriasis Day, October 29th, the international psoriatic disease community unites to raise awareness and fight for progress. The theme of 2023, "Access for All," underscores the vital need for Universal Health Coverage (UHC) to ensure t...
2023-10-26 16:00
2101
Prof. Yongmei Yin at 2023 ESMO: SKB264 (MK-2870), an innovativeTROP2-ADC originating from Chinese biotech, achieves remarkable success in overcoming the therapeutic impasse in HR+/HER2- metastatic breast cancer
CHENGDU, China, Oct. 26, 2023 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) convened its annual meeting inMadrid, Spain, from October 20th to 24th, 2023. As the preeminent academic gathering in the field ofoncology, it brought together global experts in oncology to share the la...
2023-10-26 12:58
2146
The International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair Held
PHUKET, Thailand, Oct. 26, 2023 /PRNewswire/ -- During the period from October 25 to 27, 2023, the International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair is held in Thailand. Over 200 experts and scholars from more than 20 countries ...
2023-10-26 10:29
1832
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
* The independent data monitoring committee (IDMC) recommended the continuation of the BBT-877 Phase 2a trial based on the initial clinical data from the first 20 participants dosed with theinvestigational product * No safety concerns were raised based on the evaluation of the data presented ...
2023-10-26 07:00
1688
Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology
SUNNYVALE, Calif., Oct. 25, 2023 /PRNewswire/ -- EBR Systems, Inc.
2023-10-26 00:00
1870
Neuragenex Brings Innovative Fibromyalgia Treatment to Patients Across the US
GULBERT, Ariz., Oct. 25, 2023 /PRNewswire/ -- Neuragenex, the national healthcare provider focused on non-pharmaceutical pain treatment, announced its continued expansion to bring relief to fibromyalgia patients across the country. With clinics now operating in Georgia, Texas, Illinois, Tenness...
2023-10-25 23:23
1394
Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer
JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...
2023-10-25 22:33
2113
Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer
JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...
2023-10-25 22:15
1982
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe
SHANGHAI, Oct. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient inEurope has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination ...
2023-10-25 21:15
2016
FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic
* FDA INTERACT meeting reviews Turn Bio's ERA™ and eTurna™ technologies, approach and plans, paving way toward its IND * Company continues to pace industry's cell regeneration therapy progress MOUNTAIN VIEW, Calif., Oct. 25, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation compa...
2023-10-25 20:30
1839
ESAOTE's new S-scan Open redefines excellence in magnetic resonance imaging
GENOA, Italy, Oct. 25, 2023 /PRNewswire/ -- Esaote, a leading Italian company
in ultrasound, dedicated MRI and healthcare IT,presents S-scan Open, the new
configuration of S-scan,one of its best-selling MRI systems.
2023-10-25 20:00
2347
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 307 media titles]
2025-01-07 09:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 305 media titles]
2025-01-06 14:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 292 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 290 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10334
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
2025-01-02 08:16
8071
PieX AI: Launching the World's First Personalized, On-device AI Pendant at CES 2025
2025-01-02 21:00
6290
